Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
European Journal of Pharmacology
|
April 12, 2016
Preface
Marcus Maurer, Frank Redegeld
Plos One
|
January 28, 2025
Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin
Jahan Abdi, Frank Redegeld
Clinical Nutrition (Edinburgh, Scotland)
|
September 26, 2020
The efficacy of bortezomib in human multiple myeloma cells is enhanced by combination with omega-3 fatty acids DHA and EPA: Timing is essential
Jing Chen, Johan Garssen, Frank Redegeld
Pulmonary Pharmacology & Therapeutics
|
April 6, 2011
Mast cells and COPD
Esmaeil Mortaz, Gert Folkerts, Frank Redegeld
Critical Reviews in Oncology/Hematology
|
January 18, 2011
The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma
Jahangir Abdi, Ferdi Engels, Johan Garssen, et al.
European Journal of Pharmacology
|
February 4, 2006
Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases
Maurice van der Heijden, Aletta Kraneveld, Frank Redegeld
Current Opinion in Allergy and Clinical Immunology
|
July 11, 2007
Animal models of anaphylaxis
Alma Nauta, Leon Knippels, Johan Garssen, et al.
Plos One
|
April 18, 2013
Characterization of the Toll-like receptor expression profile in human multiple myeloma cells
Jahangir Abdi, Tuna Mutis, Johan Garssen, et al.
Cells
|
November 27, 2019
Molecular Insights into the Mechanism of Necroptosis: The Necrosome As a Potential Therapeutic Target
Jing Chen, Renate Kos, Johan Garssen, et al.
Neuroscience and Biobehavioral Reviews
|
June 16, 2025
The role of mast cells in Autism Spectrum Disorder
Laura Priego-González, Paula Perez Pardo, Frank Redegeld
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
European Journal of Pharmacology
|
April 12, 2016
Preface
Marcus Maurer, Frank Redegeld
Plos One
|
January 28, 2025
Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin
Jahan Abdi, Frank Redegeld
Clinical Nutrition (Edinburgh, Scotland)
|
September 26, 2020
The efficacy of bortezomib in human multiple myeloma cells is enhanced by combination with omega-3 fatty acids DHA and EPA: Timing is essential
Jing Chen, Johan Garssen, Frank Redegeld
Pulmonary Pharmacology & Therapeutics
|
April 6, 2011
Mast cells and COPD
Esmaeil Mortaz, Gert Folkerts, Frank Redegeld
Critical Reviews in Oncology/Hematology
|
January 18, 2011
The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma
Jahangir Abdi, Ferdi Engels, Johan Garssen, et al.
European Journal of Pharmacology
|
February 4, 2006
Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases
Maurice van der Heijden, Aletta Kraneveld, Frank Redegeld
Current Opinion in Allergy and Clinical Immunology
|
July 11, 2007
Animal models of anaphylaxis
Alma Nauta, Leon Knippels, Johan Garssen, et al.
Plos One
|
April 18, 2013
Characterization of the Toll-like receptor expression profile in human multiple myeloma cells
Jahangir Abdi, Tuna Mutis, Johan Garssen, et al.
Cells
|
November 27, 2019
Molecular Insights into the Mechanism of Necroptosis: The Necrosome As a Potential Therapeutic Target
Jing Chen, Renate Kos, Johan Garssen, et al.
Neuroscience and Biobehavioral Reviews
|
June 16, 2025
The role of mast cells in Autism Spectrum Disorder
Laura Priego-González, Paula Perez Pardo, Frank Redegeld
Page
of 4